🇺🇸 FDA
Patent

US 11365230

Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

granted A61KA61K31/675A61K39/0011

Quick answer

US patent 11365230 (Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof) held by IMMUNE DESIGN CORP. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
IMMUNE DESIGN CORP.
Grant date
Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/675, A61K39/0011, A61K39/12, A61P